Zevalin Added to SCT Boosts Survival in Refractory Follicular Lymphoma

Spectrum Pharmaceuticals is announcing that positive long-term clinical data for the Zevalin® therapeutic regimen has been published in the journal of the American Society of Hematology Blood regarding the treatment of patients diagnosed with late-stage relapsed follicular non-Hodgkin’s lymphoma (fNHL).

The data was first reported last December at the American Society of Hematology annual meeting as an abstract.

Typically, fNHL patients whose disease is chemo-refractory have a poorer prognosis. After having relapsed three times after treatment, these patients have a median survival of 1.5 years.

In the study, 26 of these patients received the Zevalin regimen following the administration of the combination chemotherapy regimen fludarabine, cyclophosphamide, and rituximab (FCR). The chemotherapy was given as a preparative regimen prior to a nonmyeloablative allogeneic stem cell transplantation (NST).

Patients were evaluated four times in the year following the transplant, then twice yearly for up to five years. The median follow-up duration was 33 months. Researchers determined that the patients experienced a substantially higher 6-year overall survival (OS) estimate of 80%--a huge improvement over the previous median survival times.

“It is very encouraging to see the publication of long-term clinical data showing that Zevalin's usage in this allogeneic transplantation regimen can contribute to improved overall survival" in this patient population, said Spectrum's President and CEO Rajesh C. Shrotriya, M.D. He continued:

"These data are very important to understanding the benefit of Zevalin in patients who receive allogeneic stem cells from donors and build on previously published and presented findings for autologous stem cell approach in these refractory patients. These data help solidify a role of ZEVALIN in stem cell transplantation.”

More Articles

More Articles

Mantle cell lymphoma (MCL) is a rare type of B-Cell lymphoma. It presents itself in the mantle zone of lymph nodes...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

Lymphomas are classified based on the type of cells involved. Non-Hodgkin’s lymphomas are marked by mutations of...

Hodgkin's Lymphoma (Disease) has a colorful history: It was not the first cancer discovered but it was one of the first in which treatments were...

There are two types of cancer: benign and malignant. Benign cancers are the kind that don't spread and don't threaten one's life. Malignant...

Cancer bracelets are undeniably popular, and if purchased through reliable sources such as major charities, they help contribute to the fight...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer of the b- and t-cell lymphocytes, part of the immune system. They account for the most frequent head and neck malignancies....

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...

As a kind of cancer, lymphoma attacks the lymphocytes and lymph nodes that are part of the immune system. Head and neck lymphoma results when...

Some cancers have clear environmental causes. Oral cancer is strongly tied to the use of chewing tobacco, and lung cancer is well-known to be much...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...